TAI’AN, China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (“China Biologic,” or the “Company”), one of the leading plasma-based pharmaceutical companies in the People’s Republic of China (“PRC”), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. (“Taibang”) and Chongqing Dalin Biologic Technologies Co., Ltd. (“Dalin”) and its equity investment in Xi’an Huitian Blood Products Co., Ltd. (“Huitian”), today announced that the Company’s management team will attend the upcoming Rodman & Renshaw Annual Global Investment Conference.
The date, time and location of China Biologic’s presentation at the conference are as follows:
During the conference, the Company will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with China Biologic’s management may contact mwoodson@rodm.com or call (212) 430-1782. Participation in the Rodman & Renshaw Annual Global Investment Conference is by invitation only.
About Rodman & Renshaw, LLC.
Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the “Company”), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi’an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company’s plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.
SOURCE China Biologic Products, Inc.
CONTACT: Company Contact: Mr. Y. Tristan Kuo, Chief Financial Officer of
China Biologic Products, Inc., +86-538-6202206, or IR@chinabiologic.com;
Investor Relations Contact: Mr. Crocker Coulson, President of CCG Investor
Relations, +1-646-213-1915 (NY office) or Mr. Gary Chin, +1-646-213-1909,
or crocker.coulson@ccgir.com
Web site: http://www.chinabiologic.com/
